MA63248B1 - Formulations d'un inhibiteur de la kallicréine plasmatique - Google Patents
Formulations d'un inhibiteur de la kallicréine plasmatiqueInfo
- Publication number
- MA63248B1 MA63248B1 MA63248A MA63248A MA63248B1 MA 63248 B1 MA63248 B1 MA 63248B1 MA 63248 A MA63248 A MA 63248A MA 63248 A MA63248 A MA 63248A MA 63248 B1 MA63248 B1 MA 63248B1
- Authority
- MA
- Morocco
- Prior art keywords
- tablets
- orodispersible
- inhibitor
- plasma
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des formes posologiques pharmaceutiques sous forme de comprimés orodispersibles comprenant un inhibiteur de la kallicréine plasmatique, des mélanges destinés à être utilisés dans des procédés de fabrication pour produire les comprimés orodispersibles de l'invention et les utilisations de tels comprimés orodispersibles. Les comprimés orodispersibles de la présente invention conviennent particulièrement pour des patients qui ont du mal à avaler des comprimés. La présente invention concerne des traitements à la demande de l'angio-œdème médié par la bradykinine par administration par voie orale d'un inhibiteur de la kallicréine plasmatique à un patient qui en a besoin sous la forme d'un comprimé orodispersible.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335387P | 2022-04-27 | 2022-04-27 | |
| PCT/GB2023/051120 WO2023209381A1 (fr) | 2022-04-27 | 2023-04-27 | Formulations d'un inhibiteur de la kallicréine plasmatique |
| EP23722929.9A EP4288036B1 (fr) | 2022-04-27 | 2023-04-27 | Formulations d'un inhibiteur de la kallicréine plasmatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63248B1 true MA63248B1 (fr) | 2024-11-29 |
Family
ID=86330823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63248A MA63248B1 (fr) | 2022-04-27 | 2023-04-27 | Formulations d'un inhibiteur de la kallicréine plasmatique |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20250281397A1 (fr) |
| EP (2) | EP4480545A3 (fr) |
| JP (1) | JP2025514861A (fr) |
| KR (1) | KR20250002615A (fr) |
| CN (1) | CN119095589A (fr) |
| AU (1) | AU2023262237A1 (fr) |
| CA (1) | CA3255900A1 (fr) |
| CL (1) | CL2024003252A1 (fr) |
| CO (1) | CO2024014871A2 (fr) |
| DK (1) | DK4288036T3 (fr) |
| ES (1) | ES2991820T3 (fr) |
| FI (1) | FI4288036T3 (fr) |
| HR (1) | HRP20241160T1 (fr) |
| HU (1) | HUE068435T2 (fr) |
| IL (1) | IL316435A (fr) |
| LT (1) | LT4288036T (fr) |
| MA (1) | MA63248B1 (fr) |
| MD (1) | MD4288036T2 (fr) |
| MX (1) | MX2024013084A (fr) |
| PL (1) | PL4288036T3 (fr) |
| PT (1) | PT4288036T (fr) |
| RS (1) | RS66161B1 (fr) |
| SI (1) | SI4288036T1 (fr) |
| SM (1) | SMT202400372T1 (fr) |
| WO (1) | WO2023209381A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025172692A1 (fr) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire |
| WO2025172693A1 (fr) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire |
| WO2026003532A1 (fr) | 2024-06-28 | 2026-01-02 | Kalvista Pharmaceuticals Limited | Sébetralstat pour le traitement de l'anxiété associée à un angioedème héréditaire |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2008016883A2 (fr) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibiteurs de kallicréine plasmatique |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (fr) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Inhibiteurs de la sérine protéase |
| EP2595986A2 (fr) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| EP2999697B1 (fr) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Dérivés hétérocycliques |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201721515D0 (en) | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2022079446A1 (fr) * | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Traitements de l'œdème de quincke |
-
2023
- 2023-04-27 EP EP24192826.6A patent/EP4480545A3/fr active Pending
- 2023-04-27 WO PCT/GB2023/051120 patent/WO2023209381A1/fr not_active Ceased
- 2023-04-27 DK DK23722929.9T patent/DK4288036T3/da active
- 2023-04-27 SM SM20240372T patent/SMT202400372T1/it unknown
- 2023-04-27 CA CA3255900A patent/CA3255900A1/fr active Pending
- 2023-04-27 MA MA63248A patent/MA63248B1/fr unknown
- 2023-04-27 EP EP23722929.9A patent/EP4288036B1/fr active Active
- 2023-04-27 PT PT237229299T patent/PT4288036T/pt unknown
- 2023-04-27 LT LTEPPCT/GB2023/051120T patent/LT4288036T/lt unknown
- 2023-04-27 AU AU2023262237A patent/AU2023262237A1/en active Pending
- 2023-04-27 FI FIEP23722929.9T patent/FI4288036T3/fi active
- 2023-04-27 PL PL23722929.9T patent/PL4288036T3/pl unknown
- 2023-04-27 SI SI202330007T patent/SI4288036T1/sl unknown
- 2023-04-27 IL IL316435A patent/IL316435A/en unknown
- 2023-04-27 RS RS20241199A patent/RS66161B1/sr unknown
- 2023-04-27 KR KR1020247038822A patent/KR20250002615A/ko active Pending
- 2023-04-27 ES ES23722929T patent/ES2991820T3/es active Active
- 2023-04-27 MD MDE20231179T patent/MD4288036T2/ro unknown
- 2023-04-27 HR HRP20241160TT patent/HRP20241160T1/hr unknown
- 2023-04-27 CN CN202380036493.1A patent/CN119095589A/zh active Pending
- 2023-04-27 US US18/859,650 patent/US20250281397A1/en active Pending
- 2023-04-27 JP JP2024563310A patent/JP2025514861A/ja active Pending
- 2023-04-27 HU HUE23722929A patent/HUE068435T2/hu unknown
-
2024
- 2024-10-23 MX MX2024013084A patent/MX2024013084A/es unknown
- 2024-10-24 CL CL2024003252A patent/CL2024003252A1/es unknown
- 2024-10-30 CO CONC2024/0014871A patent/CO2024014871A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023262237A1 (en) | 2024-10-31 |
| PT4288036T (pt) | 2024-10-23 |
| CA3255900A1 (fr) | 2023-11-02 |
| HRP20241160T1 (hr) | 2024-11-22 |
| DK4288036T3 (da) | 2024-08-26 |
| PL4288036T3 (pl) | 2024-11-25 |
| MD4288036T2 (ro) | 2025-02-28 |
| CO2024014871A2 (es) | 2024-12-09 |
| LT4288036T (lt) | 2024-09-25 |
| EP4480545A2 (fr) | 2024-12-25 |
| SMT202400372T1 (it) | 2024-11-15 |
| HUE068435T2 (hu) | 2024-12-28 |
| RS66161B1 (sr) | 2024-12-31 |
| ES2991820T3 (es) | 2024-12-05 |
| WO2023209381A1 (fr) | 2023-11-02 |
| CN119095589A (zh) | 2024-12-06 |
| CL2024003252A1 (es) | 2025-02-14 |
| EP4288036A1 (fr) | 2023-12-13 |
| EP4288036B1 (fr) | 2024-08-07 |
| US20250281397A1 (en) | 2025-09-11 |
| FI4288036T3 (fi) | 2024-08-29 |
| JP2025514861A (ja) | 2025-05-09 |
| IL316435A (en) | 2024-12-01 |
| SI4288036T1 (sl) | 2024-10-30 |
| EP4480545A3 (fr) | 2025-02-26 |
| KR20250002615A (ko) | 2025-01-07 |
| MX2024013084A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA63248B1 (fr) | Formulations d'un inhibiteur de la kallicréine plasmatique | |
| WO2005065069A3 (fr) | Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer | |
| JP2025106310A (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| DK0794794T3 (da) | Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler | |
| DE60121301D1 (de) | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen | |
| BR9909672A (pt) | uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| JP2006506378A5 (fr) | ||
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| JP2018514589A5 (fr) | ||
| Epstein et al. | Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| JP2024524434A (ja) | うつ状態を処置するための方法 | |
| JP2021502392A5 (fr) | ||
| DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
| JP2011111418A (ja) | 口腔内局所投与に適したウイルス感染予防製剤 | |
| HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
| SE0102887D0 (sv) | New formulation | |
| KR20200066664A (ko) | 세균 감염증을 치료하는 방법 | |
| JPH06505733A (ja) | ミクロスポリディア症の治療におけるベンゾイミダゾール駆虫薬の使用 |